We Spent $724,637 Testing Rapamycin. What We Found Shocked Us.

Why It Matters

The trial’s surprising result that rapamycin may blunt exercise‑induced muscle improvements challenges its presumed anti‑aging benefits and signals that dosing strategies must be refined before clinical adoption.

Key Takeaways

• $724,637 funded 5‑year rapamycin trial in older adults.
• Primary muscle strength test showed no significant benefit over placebo.
• Sensitivity analyses suggested placebo outperformed rapamycin in functional gains.
• Study design was rigorous, pre‑registered, but sample size limited.
• Findings raise questions about dosing schedule and rapamycin’s role in humans.

Summary

The video details a five‑year, $724,637 crowdfunded clinical trial that tested whether weekly rapamycin, combined with home‑based cycling exercise, could improve muscle performance in adults aged 65‑85. Results were published in the Journal of Cexia Psychopenia and Muscle, and the investigators emphasize the study’s rigorous, pre‑registered design.

Forty participants were randomized to receive either 6 mg rapamycin or placebo, exercising on stationary bikes three times per week for 12 weeks. The primary endpoint, the 30‑second chair‑stand test, did not reach statistical significance; the placebo group actually trended toward greater improvement. Sensitivity analyses (case‑complete and per‑protocol) reinforced this trend, and secondary measures such as the 6‑minute walk and hand‑grip strength showed similar, non‑significant patterns favoring placebo.

Co‑author Professor Matt Kaline highlighted rapamycin’s reputation as a “gold‑standard” anti‑aging drug and explained the mechanistic hypothesis: intermittent mTOR inhibition could restore autophagy in aged muscle. He also cautioned against over‑interpreting the findings, noting the study’s limited sample size and the inherent variability of human performance data.

The unexpected attenuation of exercise gains by rapamycin suggests that the current weekly dosing schedule may be suboptimal for healthy older adults. The trial underscores the need for larger, longer‑duration studies to clarify rapamycin’s role in human healthspan and to refine dosing protocols before broader clinical adoption.

Original Description

Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70274

🩺 Get your personalized health plan: https://drstanfield.com/pages/roadmap

Timestamps:

00:00 Background of the Rapamycin Study

05:44 Study Design and Protocol

07:33 - Results of the Rapamycin Study

09:29 Interpretation of the Results

26:28 Study Conclusion and Mechanistic Explanations

31:47 Discussion on the Impact of Rapamycin on Exercise

32:41 Discussion on Future Research and Dosing Frequency

💊 Supplements I Take: https://drstanfield.com/pages/my-supplements

💊MicroVitamin+ (Pro) Powder: https://drstanfield.com/products/microvitamin-plus

💊MicroVitamin Standard Capsules: https://drstanfield.com/products/microvitamin

✔️ X: https://x.com/BradStanfieldMD

✔️ Patreon: https://www.patreon.com/bradstanfieldmd

Thumbnail by James Kelly

Video edited by Troy Young

The links above are affiliate links, so I receive a small commission every time you use them to purchase a product. The content contained in this video, and its accompanying description, is not intended to replace viewers’ relationships with their own medical practitioner. Always speak with your doctor regarding the content of this channel, and especially before using any products, services, or devices discussed on this channel.